0001209191-16-147486.txt : 20161031 0001209191-16-147486.hdr.sgml : 20161031 20161031165035 ACCESSION NUMBER: 0001209191-16-147486 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20161031 FILED AS OF DATE: 20161031 DATE AS OF CHANGE: 20161031 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Ra Pharmaceuticals, Inc. CENTRAL INDEX KEY: 0001481512 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 262908274 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: ONE KENDALL SQUARE STREET 2: SUITE B14301 CITY: CAMBRIDGE STATE: MA ZIP: 02139 BUSINESS PHONE: (617) 401-4060 MAIL ADDRESS: STREET 1: ONE KENDALL SQUARE STREET 2: SUITE B14301 CITY: CAMBRIDGE STATE: MA ZIP: 02139 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: KOLLURI KRISHNA KITTU CENTRAL INDEX KEY: 0001270521 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-37926 FILM NUMBER: 161962215 4 1 doc4.xml FORM 4 SUBMISSION X0306 4 2016-10-31 0 0001481512 Ra Pharmaceuticals, Inc. RARX 0001270521 KOLLURI KRISHNA KITTU 1954 GREENSPRING DRIVE SUITE 600 TIMONIUM MD 21093 0 0 1 0 Common Stock 2016-10-31 4 X 0 80658 0.07 A 80658 I See Note 2 Common Stock 2016-10-31 4 S 0 435 13.00 D 80223 I See Note 2 Common Stock 2016-10-31 4 C 0 1778227 A 1858450 I See Note 2 Common Stock 2016-10-31 4 C 0 669951 A 2528401 I See Note 2 Common Stock 2016-10-31 4 C 0 623210 A 3151611 I See Note 2 Common Stock 2016-10-31 4 P 0 338462 13.00 A 3490073 I See Note 2 Warrants to Purchase Common Stock 0.07 2016-10-31 4 X 0 80658 0.00 D 2022-04-01 Common Stock 80658 0 I See Note 2 Series A Preferred Stock 2016-10-31 4 C 0 12447605 0.00 D Common Stock 1778227 0 I See Note 2 Series B-1 Preferred Stock 2016-10-31 4 C 0 4689657 0.00 D Common Stock 669951 0 I See Note 2 Series B-2 Preferred Stock 2016-10-31 4 C 0 4362472 0.00 D Common Stock 623210 0 I See Note 2 The Warrants automatically exercised immediately prior to the closing of the Issuer's initial public offering for such number of shares issuable pursuant to a cashless net exercise provision, resulting in the Issuer withholding 435 of the warrant shares to pay the exercise price and issuing to the reporting person the remaining 80,223 shares, after deducting the aggregate exercise price. The Reporting Person is a director of NEA 13 GP, LTD, which is the sole general partner of NEA Partners 13, L.P. ("NEA Partners 13"). NEA Partners 13 is the sole general partner of New Enterprise Associates 13, L.P. ("NEA 13"), which is the direct beneficial owner of the securities. The Reporting Person disclaims beneficial ownership, within the meaning of Section 16 of the Securities Exchange Act of 1934, as amended, or otherwise of such portion of the NEA 13 shares in which the Reporting Person has no pecuniary interest. Each share of the Series A Preferred Stock is convertible into Common Stock on a 1-for-7 basis automatically upon the closing of the Issuer's initial public offering, and has no expiration date. Each share of the Series B-1 Preferred Stock is convertible into Common Stock on a 1-for-7 basis automatically upon the closing of the Issuer's initial public offering, and has no expiration date. Each share of the Series B-2 Preferred Stock is convertible into Common Stock on a 1-for-7 basis automatically upon the closing of the Issuer's initial public offering, and has no expiration date. /s/ Sasha Keough, attorney-in-fact 2016-10-31